Literature DB >> 8813686

Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate.

K C Williamson1, H Fujioka, M Aikawa, D C Kaslow.   

Abstract

During Plasmodium falciparum gametocytogenesis, Pfs230, a malaria transmission-blocking vaccine candidate, is expressed as a 360 kDa protein localized to the parasitophorous vacuole/parasite plasma membrane. When gametocytes emerge from red blood cells, as they do when taken up in a blood meal by a mosquito, Pfs230 is processed from a 360 kDa form to a 310 kDa form the latter of which is exposed on the exterior surface of gametes. The 50 kDa portion of Pfs230, removed from the amino-terminus of the 360 kDa form, contains 25 contiguous glutamates and an EEVG16 repeat. Analogous to other P. falciparum proteins, the repeat region appears to be immunodominant. As the gamete emerges from the red blood cell and is exposed to the antibodies in the blood meal, cleavage of the immunodominant region of Pfs230 may contribute to an immune evasion strategy by the parasite.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813686     DOI: 10.1016/s0166-6851(96)02621-7

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  13 in total

Review 1.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 3.  The s48/45 six-cysteine proteins: mediators of interaction throughout the Plasmodium life cycle.

Authors:  Silvia A Arredondo; Stefan H I Kappe
Journal:  Int J Parasitol       Date:  2016-11-27       Impact factor: 3.981

4.  Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230.

Authors:  J Healer; D McGuinness; P Hopcroft; S Haley; R Carter; E Riley
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

Review 5.  Gametocytogenesis in malaria parasite: commitment, development and regulation.

Authors:  Zhenyu Liu; Jun Miao; Liwang Cui
Journal:  Future Microbiol       Date:  2011-11       Impact factor: 3.165

6.  Expression of equi merozoite antigen 2 during development of Babesia equi in the midgut and salivary gland of the vector tick Boophilus microplus.

Authors:  Massaro W Ueti; Guy H Palmer; Lowell S Kappmeyer; Glen A Scoles; Donald P Knowles
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 7.  The coming-out of malaria gametocytes.

Authors:  Andrea Kuehn; Gabriele Pradel
Journal:  J Biomed Biotechnol       Date:  2010-01-05

8.  Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites.

Authors:  Sheetij Dutta; J David Haynes; J Kathleen Moch; Arnoldo Barbosa; David E Lanar
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-02       Impact factor: 11.205

9.  Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.

Authors:  M C Kapulu; D F Da; K Miura; Y Li; A M Blagborough; T S Churcher; D Nikolaeva; A R Williams; A L Goodman; I Sangare; A V Turner; M G Cottingham; A Nicosia; U Straschil; T Tsuboi; S C Gilbert; Carole A Long; R E Sinden; S J Draper; A V S Hill; A Cohuet; S Biswas
Journal:  Sci Rep       Date:  2015-06-11       Impact factor: 4.379

10.  Plasmodium falciparum Gametocyte-Specific Antibody Profiling Reveals Boosting through Natural Infection and Identifies Potential Markers of Gametocyte Exposure.

Authors:  Jeff Skinner; Chiung-Yu Huang; Michael Waisberg; Philip L Felgner; Ogobara K Doumbo; Aissata Ongoiba; Kassoum Kayentao; Boubacar Traore; Peter D Crompton; Kim C Williamson
Journal:  Infect Immun       Date:  2015-08-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.